본문 바로가기
KERD
논문KCI 등재

Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis

Jian-Gao Fan|Yi-Wen Shi
대한간학회 (The korean Association for the Study of the Liver)|2023.02|Clinical and Molecular Hepatology|제29권 제1호|pp. 228-243

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Disease progressionNoninvasive diagnosisRisk stratificationNonalcoholic steatohepatitisTreatment efficacy

초록

Nonalcoholic steatohepatitis (NASH) is an aggressive form of nonalcoholic fatty liver disease (NAFLD) characterized by steatosis-associated inflammation and liver injury. Without effective treatment or management, NASH can have life-threatening outcomes. Evaluation and identification of NASH patients at risk for adverse outcomes are therefore important. Key issues in screening NASH patients are the assessment of advanced fibrosis, differentiation of NASH from simple steatosis, and monitoring of dynamic changes during follow-up and treatment. Currently, NASH staging and evaluation of the effectiveness for drugs still rely on pathological diagnosis, despite sample error issues and the subjectivity associated with liver biopsy. Optimizing the pathological assessment of liver biopsy samples and developing noninvasive surrogate methods for accessible, accurate, and safe evaluation are therefore critical. Although noninvasive methods including elastography, serum soluble biomarkers, and combined models have been implemented in the last decade, noninvasive diagnostic measurements are not widely applied in clinical practice. More work remains to be done in establishing cost-effective strategies both for screening for at-risk NASH patients and identifying changes in disease severity. In this review, we summarize the current state of noninvasive methods for detecting steatosis, steatohepatitis, and fibrosis in patients with NASH, and discuss noninvasive assessments for screening at-risk patients with a focus on the characteristics that should be monitored at follow-up.

Abstract

Nonalcoholic steatohepatitis (NASH) is an aggressive form of nonalcoholic fatty liver disease (NAFLD) characterized by steatosis-associated inflammation and liver injury. Without effective treatment or management, NASH can have life-threatening outcomes. Evaluation and identification of NASH patients at risk for adverse outcomes are therefore important. Key issues in screening NASH patients are the assessment of advanced fibrosis, differentiation of NASH from simple steatosis, and monitoring of dynamic changes during follow-up and treatment. Currently, NASH staging and evaluation of the effectiveness for drugs still rely on pathological diagnosis, despite sample error issues and the subjectivity associated with liver biopsy. Optimizing the pathological assessment of liver biopsy samples and developing noninvasive surrogate methods for accessible, accurate, and safe evaluation are therefore critical. Although noninvasive methods including elastography, serum soluble biomarkers, and combined models have been implemented in the last decade, noninvasive diagnostic measurements are not widely applied in clinical practice. More work remains to be done in establishing cost-effective strategies both for screening for at-risk NASH patients and identifying changes in disease severity. In this review, we summarize the current state of noninvasive methods for detecting steatosis, steatohepatitis, and fibrosis in patients with NASH, and discuss noninvasive assessments for screening at-risk patients with a focus on the characteristics that should be monitored at follow-up.

참고문헌 (118)

  1. Riazi K, "The prevalence and incidence of NAFLD worldwide : A systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 7, pp.851~861 (2022)
  2. Jaejun Lee, "Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population- based cross-sectional study", Clinical and Molecular Hepatology, 28(2), pp.196~206 (2022), 대한간학회[DOI]
  3. Cotter TG, "Nonalcoholic fatty liver disease 2020 : The state of the disease", Gastroenterology, 158, pp.1851~1864 (2020)
  4. Michael H. Le, "Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach", Clinical and Molecular Hepatology, 28(4), pp.841~850 (2022), 대한간학회
  5. Sheka AC, "Nonalcoholic steatohepatitis : A review", JAMA, 323, pp.1175~1183 (2020)
  6. Tan DJH, "Global burden of liver cancer in males and females : Changing etiological basis and the growing contribution of NASH", Hepatology (2022)[DOI]
  7. Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
  8. Bedossa P, "Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients", Hepatology, 56, pp.1751~1759 (2012)
  9. Younossi ZM, "AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease : Expert review", Gastroenterology, 160, pp.912~918 (2021)
  10. "Draft reflection paper on regulatory requirements for the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH) -Scientific guideline"[URL]
  11. "Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment; draft guidance for industry; availability. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER)"[URL]
  12. Dulai PS, "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease : systematic review and meta-analysis", Hepatology, 65, pp.1557~1565 (2017)
  13. 강성희, "KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.363~401 (2021), 대한간학회
  14. Angulo P, "Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease", Gastroenterology, 149, pp.389~397 (2015)
  15. Taylor RS, "Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease : A systematic review and meta-analysis", Gastroenterology, 158, pp.1611~1625 (2020)
  16. Männistö VT, "Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease", Liver Int, 41, pp.2590~2600 (2021)
  17. Simon TG, "Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease : A population-based cohort study", Hepatology, 74, pp.2410~2423 (2021)
  18. Sanyal AJ, "Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis", Hepatology, 75, pp.1235~1246 (2022)
  19. Hwang Sik Shin, "Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases", Clinical and Molecular Hepatology, 28(4), pp.773~789 (2022), 대한간학회
  20. Marra F, "Lipotoxicity and the gut-liver axis in NASH pathogenesis", J Hepatol, 68, pp.280~295 (2018)
  21. Marengo A, "Progression and natural history of nonalcoholic fatty liver disease in adults", Clin Liver Dis, 20, pp.313~324 (2016)
  22. Koyama Y, "Liver inflammation and fibrosis", J Clin Invest, 127, pp.55~64 (2017)
  23. Singh S, "Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis : A systematic review and meta-analysis of paired-biopsy studies", Clin Gastroenterol Hepatol, 13, pp.643~654 (2015)
  24. Shi Y, "The prevalence of lean", nonobese nonalcoholic fatty liver disease : A systematic review and meta-analysis, 2020, pp.54, 378~387
  25. Zeng J, "Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease", World J Gastroenterol, 26, pp.1792~1804 (2020)
  26. Fan J, "NAFLD in Chinese : Growing concern and management strategy", Hong Kong Medical Diary, 25, pp.16~17 (2020)
  27. Fan JG, "New trends on obesity and NAFLD in Asia", J Hepatol, 67, pp.862~873 (2017)
  28. Younossi ZM, "Clinical and economic burden of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis", Clin Liver Dis, 22, pp.1~10 (2018)
  29. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : Practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
  30. Kanwal F, "Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease", Hepatology, 71, pp.808~819 (2020)
  31. Hwi Young Kim, "Recent advances in nonalcoholic fatty liver disease metabolomics", Clinical and Molecular Hepatology, 27(4), pp.553~559 (2021), 대한간학회[DOI]
  32. Won Sohn, "Obesity and the risk of primary liver cancer: A systematic review and meta-analysis", Clinical and Molecular Hepatology, 27(1), pp.157~174 (2021), 대한간학회[DOI]
  33. Younossi ZM, "In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not", Metabolism, 62, pp.352~360 (2013)
  34. Mantovani A, "Non-alcoholic fatty liver disease and risk of incident diabetes mellitus : An updated meta-analysis of 501 022 adult individuals", Gut, 70, pp.962~969 (2021)
  35. Zaharia OP, "Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: A 5-year follow-up study", Lancet Diabetes Endocrinol, 7, pp.684~694 (2019)
  36. Shi YW, "Metabolic disorders combined with noninvasive tests to screen advanced fibrosis in nonalcoholic fatty liver disease", J Clin Transl Hepatol, 9, pp.607~614 (2021)
  37. Lonardo A, "Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?", J Hepatol, 68, pp.335~352 (2018)
  38. Bedossa P, "Utility and appropriateness of the fatty liver inhibition of progression(FLIP)algorithm and steatosis, activity, and fibrosis(SAF)score in the evaluation of biopsies of nonalcoholic fatty liver disease", Hepatology, 60, pp.565~575 (2014)
  39. Gailhouste L, "Fibrillar collagen scoring by second harmonic microscopy : A new tool in the assessment of liver fibrosis", J Hepatol, 52, pp.398~406 (2010)
  40. Goh GB, "Quantification of hepatic steatosis in chronic liver disease using novel automated method of second harmonic generation and two-photon excited fluorescence", Sci Rep, 9, pp.2975~ (2019)
  41. Harrison SA, "In a placebo-controlled 36-week phase 2 trial, treatment with MGL-3196 compared to placebo results in significant reductions in hepatic fat(MRI-PDFF), liver enzymes, fibrosis biomarkers, atherogenic lipids, and improvement in NASH on serial liver biopsy", Hepatology, 68(Suppl), pp.9A~10A (2018)
  42. Wang Y, "Dual-photon microscopy-based quantitation of fibrosisrelated parameters(q-FP)to model disease progression in steatohepatitis", Hepatology, 65, pp.1891~1903 (2017)
  43. Liu F, "qFIBS : An automated technique for quantitative evaluation of fibrosis, inflammation, ballooning, and steatosis in patients with nonalcoholic steatohepatitis", Hepatology, 71, pp.1953~1966 (2020)
  44. Naoumov NV, "Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH", J Hepatol, 77, pp.1399~1409 (2022)
  45. Marti-Aguado D, "Digital pathology : Accurate technique for quantitative assessment of histological features in metabolic-associated fatty liver disease", Aliment Pharmacol Ther, 53, pp.160~171 (2021)
  46. Masugi Y, "Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease", Hepatol Commun, 2, pp.58~68 (2017)
  47. Munsterman ID, "A novel automatic digital algorithm that accurately quantifies steatosis in NAFLD on histopathological whole-slide images", Cytometry B Clin Cytom, 96, pp.521~528 (2019)
  48. Melo RCN, "Whole slide imaging and its applications to histopathological studies of liver disorders", Front Med(Lausanne), 6, pp.310~ (2020)
  49. Brunt EM, "Complexity of ballooned hepatocyte feature recognition : Defining a training atlas for artificial intelligence-based imaging in NAFLD", J Hepatol, 76, pp.1030~1041 (2022)
  50. Taylor-Weiner A, "A machine learning approach enables quantitative measurement of liver histology and disease monitoring in NASH", Hepatology, 74, pp.133~147 (2021)
  51. Zhu J, "Validation of simple indexes for nonalcoholic fatty liver disease in western China : A retrospective cross-sectional study", Endocr J, 65, pp.373~381 (2018)
  52. Xiao G, "Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease : A meta-analysis", Hepatology, 66, pp.1486~1501 (2017)
  53. Feldstein AE, "Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis : A multicenter validation study", Hepatology, 50, pp.1072~1078 (2009)
  54. Sumida Y, "A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease", J Gastroenterol, 46, pp.257~268 (2011)
  55. Ekstedt M, "Long-term follow-up of patients with NAFLD and elevated liver enzymes", Hepatology, 44, pp.865~873 (2006)
  56. Harrison SA, "Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease", Gut, 57, pp.1441~1447 (2008)
  57. Duarte SMB, "Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake : A prospective pilot study", Nutr Metab Cardiovasc Dis, 28, pp.369~384 (2018)
  58. Fedchuk L, "Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease", Aliment Pharmacol Ther, 40, pp.1209~1222 (2014)
  59. Foschi FG, "External validation of surrogate indices of fatty liver in the general population : The bagnacavallo study", J Clin Med, 10, pp.520~ (2021)
  60. McHenry S, "Dallas steatosis index identifies patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 18, pp.2073~2080 (2020)
  61. Angulo P, "The NAFLD fibrosis score : A noninvasive system that identifies liver fibrosis in patients with NAFLD", Hepatology, 45, pp.846~854 (2007)
  62. 이태훈, "Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score", Gut and Liver, 7(3), pp.323~328 (2013), 거트앤리버 소화기연관학회협의회
  63. Labenz C, "Predictors of advanced fibrosis in non-cirrhotic nonalcoholic fatty liver disease in Germany", Aliment Pharmacol Ther, 48, pp.1109~1116 (2018)
  64. Nielsen MJ, "Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population", J Hepatol, 75, pp.1292~1300 (2021)
  65. Tanwar S, "Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease", Hepatology, 57, pp.103~111 (2013)
  66. Nobili V, "Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease", Gastroenterology, 136, pp.160~167 (2009)
  67. Vali Y, "Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD:A systematic review and meta-analysis", J Hepatol, 73, pp.252~262 (2020)
  68. Harrison SA, "NGM282 improves liver fibrosis and histology in 12weeks in patients with nonalcoholic steatohepatitis", Hepatology, 71, pp.1198~1212 (2020)
  69. Daniels SJ, "ADAPT : An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis", Hepatology, 69, pp.1075~1086 (2019)
  70. Guillaume M, "Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and enhanced liver fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres", Aliment Pharmacol Ther, 50, pp.1214~1222 (2019)
  71. Guha IN, "Noninvasive markers of fibrosis in nonalcoholic fatty liver disease : Validating the European liver fibrosis panel and exploring simple markers", Hepatology, 47, pp.455~460 (2008)
  72. Loomba R, "Validation of serum test for advanced liver fibrosis in patients with nonalcoholic steatohepatitis", Clin Gastroenterol Hepatol, 17, pp.1867~1876 (2019)
  73. Ampuero J, "Development and validation of hepamet fibrosis scoring system-a simple, noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis", Clin Gastroenterol Hepatol, 18, pp.216~225 (2020)
  74. Verma S, "Predictive value of ALT levels for non-alcoholic steatohepatitis(NASH)and advanced fibrosis in non-alcoholic fatty liver disease(NAFLD)", Liver Int, 33, pp.1398~1405 (2013)
  75. Cusi K, "Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease", J Hepatol, 60, pp.167~174 (2014)
  76. Kawanaka M, "Correlation between serum cytokeratin-18 and the progression or regression of non-alcoholic fatty liver disease", Ann Hepatol, 14, pp.837~844 (2015)
  77. Musso G, "Meta-analysis : Natural history of non-alcoholic fatty liver disease(NAFLD)and diagnostic accuracy of non-invasive tests for liver disease severity", Ann Med, 43, pp.617~649 (2011)
  78. Kwok R, "Systematic review with meta-analysis : Non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments", Aliment Pharmacol Ther, 39, pp.254~269 (2014)
  79. Otgonsuren M, "Single non-invasive model to diagnose non-alcoholic fatty liver disease(NAFLD)and non-alcoholic steatohepatitis(NASH)", J Gastroenterol Hepatol, 29, pp.2006~2013 (2014)
  80. Younes R, "Usefulness of the index of NASH-ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver : An external validation study", Liver Int, 38, pp.715~723 (2018)
  81. Eslam M, "A new definition for metabolic dysfunction-associated fatty liver disease : An international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
  82. Kumar R, "Association of high-sensitivity C-reactive protein(hs-CRP)with non-alcoholic fatty liver disease(NAFLD)in Asian Indians : A cross-sectional study", J Family Med Prim Care, 9, pp.390~394 (2020)
  83. Pirola CJ, "Circulating microRNA signature in non-alcoholic fatty liver disease : From serum non-coding RNAs to liver histology and disease pathogenesis", Gut, 64, pp.800~812 (2015)
  84. Hyysalo J, "A population-based study on the prevalence of NASH using scores validated against liver histology", J Hepatol, 60, pp.839~846 (2014)
  85. Paige JS, "A pilot comparative study of quantitative ultrasound, conventional ultrasound, and MRI for predicting histologydetermined steatosis grade in adult nonalcoholic fatty liver disease", AJR Am J Roentgenol, 208, pp.W168~W177 (2017)
  86. Tada T, "Utility of attenuation coefficient measurement using an ultrasound-guided attenuation parameter for evaluation of hepatic steatosis : Comparison with MRI-determined proton density fat fraction", AJR Am J Roentgenol, 212, pp.332~341 (2019)
  87. de Lédinghen V, "Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease", J Gastroenterol Hepatol, 31, pp.848~855 (2016)
  88. Park CC, "Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease", Gastroenterology, 152, pp.598~607 (2017)
  89. Garg H, "Utility of transient elastography(fibroscan)and impact of bariatric surgery on nonalcoholic fatty liver disease(NAFLD)in morbidly obese patients", Surg Obes Relat Dis, 14, pp.81~91 (2018)
  90. Middleton MS, "Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis", Gastroenterology, 153, pp.753~761 (2017)
  91. Noureddin M, "Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials", Hepatology, 58, pp.1930~1940 (2013)
  92. Wells MM, "Computed tomography measurement of hepatic steatosis : Prevalence of hepatic steatosis in a Canadian population", Can J Gastroenterol Hepatol, 2016, pp.4930987~ (2016)
  93. Siddiqui MS, "Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 17, pp.156~163 (2019)
  94. Wong VW, "Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease", Hepatology, 51, pp.454~462 (2010)
  95. Tapper EB, "FibroScan(vibrationcontrolled transient elastography) : Where does it stand in the United States practice", Clin Gastroenterol Hepatol, 13, pp.27~36 (2015)
  96. Sanyal AJ, "Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScanbased Agile scores", J Hepatol (2022)[DOI]
  97. Cassinotto C, "Liver stiffness in nonalcoholic fatty liver disease : A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy", Hepatology, 63, pp.1817~1827 (2016)
  98. Chen J, "Diagnostic performance of MR elastography and vibrationcontrolled transient elastography in the detection of hepatic fibrosis in patients with severe to morbid obesity", Radiology, 283, pp.418~428 (2017)
  99. Imajo K, "Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography", Gastroenterology, 150, pp.626~637 (2016)
  100. Selvaraj EA, "Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis", J Hepatol, 75, pp.770~785 (2021)
  101. Jung J, "MRE combined with FIB-4(MEFIB)index in detection of candidates for pharmacological treatment of NASHrelated fibrosis", Gut, 70, pp.1946~1953 (2021)
  102. Noureddin M, "MRI-based(MAST)score accurately identifies patients with NASH and significant fibrosis", J Hepatol, 76, pp.781~787 (2022)
  103. Siddiqui MS, "Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science", Hepatology, 67, pp.2001~2012 (2018)
  104. Harrison SA, "A blood-based biomarker panel(NIS4)for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis : A prospective derivation and global validation study", Lancet Gastroenterol Hepatol, 5, pp.970~985 (2020)
  105. Boursier J, "Screening for therapeutic trials and treatment indication in clinical practice : MACK-3, a new blood test for the diagnosis of fibrotic NASH", Aliment Pharmacol Ther, 47, pp.1387~1396 (2018)
  106. Chuah KH, "MACK-3(combination of hoMa, Ast and CK18) : A promising novel biomarker for fibrotic non-alcoholic steatohepatitis", Liver Int, 39, pp.1315~1324 (2019)
  107. Tang LJ, "Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD", Metabolism, 128, pp.154958~ (2022)
  108. Kim BK, "Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD", J Hepatol, 77, pp.1482~1490 (2022)
  109. Andersson A, "Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression : A multicenter pooled data and meta-analysis", Clin Gastroenterol Hepatol, 20, pp.2451~2461 (2022)
  110. Corey KE, "ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD", J Hepatol, 76, pp.25~33 (2022)
  111. Starekova J, "Quantification of liver fat content with CT and MRI : State of the art", Radiology, 301, pp.250~262 (2021)
  112. Loomba R, "Multicenter validation of association between decline in MRI-PDFF and histologic response in NASH", Hepatology, 72, pp.1219~1229 (2020)
  113. Gawrieh S, "Relationship of ELF and PIIINP with liver histology and response to Vitamin E or pioglitazone in the PIVENS trial", Hepatol Commun, 5, pp.786~797 (2021)
  114. Forlano R, "NAFLD : Time to apply quantitation in liver biopsies as endpoints in clinical trials", J Hepatol, 74, pp.241~242 (2021)
  115. Buzzetti E, "Collagen proportionate area is an independent predictor of long-term outcome in patients with non-alcoholic fatty liver disease", Aliment Pharmacol Ther, 49, pp.1214~1222 (2019)
  116. Qadri S, "Obesity modifies the performance of fibrosis biomarkers in nonalcoholic fatty liver disease", J Clin Endocrinol Metab, 107, pp.e2008~e2020 (2022)
  117. Vilar-Gomez E, "Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease : A multi-national cohort study", Gastroenterology, 155, pp.443~457 (2018)
  118. Sun C, "Editorial : changes of health-related quality of life associated with liver disease severity and its improvement after treatment in NAFLD", Aliment Pharmacol Ther, 57, pp.257~258 (2023)

관련 논문AI추천

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver diseaseGrace Lai-Hung Wong, Jimmy Che-To Lai, Sherlot Juan Song, Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong, Yichong Jiang, Yue Wang대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developmentsSang Bong Ahn대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Identification of high-risk subjects in nonalcoholic fatty liver diseaseChristiane Stern, Laurent Castera대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and futureFei Lyu, Grace Lai-Hung Wong, Guanlin Li, Huapeng Lin, Pong-Chi Yuen, Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future김승업, Han Ah Lee, Jung Hwan Yu대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and futureChristopher D. Byrne, Ryan M. Buchanan, Tina Reinson대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호

이 간행물의 다른 논문 (46건)

Subclinical versus advanced forms of alcohol-related liver disease: Need for early detectionLuma Melo, David Martí-Aguado, Ramón Bataller, Concepción Gómez-Medinapp. 1-15PrefaceYoon Jun Kimpp. 2-2PrefaceSeung Up Kimpp. 3-3Non-alcoholic fatty liver disease: Definition and subtypesSeul Ki Han, 김문영, 백순구pp. 5-16Management of refractory ascitesFlorence Wongpp. 16-32
원문 보기